HGF and neoplasm: Increased expression of insulin-like growth factors −1 and −2, and hepatocyte growth factor, was observed during neoplastic progression; notably, however, no substantive alterations in the expression of these factors, or of other candidate tumor growth factors and receptors, resulted from the treatment with imatinib (Figure 4A and Table S1).